Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASRT Assertio	$0.66 +1.5%	$0.64	$0.51 ▼ $1.80	$63.39M	0.32	664,210 shs	145,315 shs
IOBT IO Biotech	$1.60 +6.7%	$1.05	$0.66 ▼ $1.73	$105.41M	0.36	279,983 shs	182,415 shs
TXMD TherapeuticsMD	$1.25 +12.6%	$1.22	$0.70 ▼ $2.44	$14.47M	0.5	159,489 shs	150,283 shs
VTVT vTv Therapeutics	$16.67	$19.15	$12.12 ▼ $26.99	$53.26M	0.77	23,350 shs	2,841 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASRT Assertio	+1.50%	-1.59%	+7.24%	-15.36%	-33.80%
IOBT IO Biotech	+6.67%	+15.94%	+62.44%	+77.78%	+32.23%
TXMD TherapeuticsMD	+12.61%	-13.79%	-9.60%	+43.68%	-40.48%
VTVT vTv Therapeutics	+0.88%	+5.57%	-18.12%	+6.78%	-12.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASRT Assertio	1.3792 of 5 stars	3.5	0.0	0.6	0.8	1.3
IOBT IO Biotech	3.6849 of 5 stars	3.7	3.0	4.1	2.5	1.3
TXMD TherapeuticsMD	1.2807 of 5 stars	0.0	5.0	1.8	1.7	0.6
VTVT vTv Therapeutics	2.7972 of 5 stars	3.5	5.0	4.1	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASRT Assertio	3.00	Buy	$2.75	315.53% Upside
IOBT IO Biotech	3.33	Buy	$9.33	483.33% Upside
TXMD TherapeuticsMD	0.00	N/A	N/A	N/A
VTVT vTv Therapeutics	3.00	Buy	$35.50	112.96% Upside

Current Analyst Ratings Breakdown

Latest TXMD, IOBT, ASRT, and VTVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.50 ➝ $3.50
5/14/2025	IOBT IO Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ASRT Assertio	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/9/2025	VTVT vTv Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$36.00
4/1/2025	IOBT IO Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
3/19/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.50
3/14/2025	ASRT Assertio	Industrial Alliance Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$1.75
3/12/2025	IOBT IO Biotech	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASRT Assertio	$119.00M	0.53	$0.59 per share	1.12	$1.46 per share	0.45
IOBT IO Biotech	N/A	N/A	N/A	N/A	$2.02 per share	N/A
TXMD TherapeuticsMD	$1.84M	7.86	N/A	N/A	$2.77 per share	0.45
VTVT vTv Therapeutics	$17K	3,132.98	N/A	N/A	($9.27) per share	-1.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASRT Assertio	-$331.94M	-$0.32	N/A	22.06	3.25	-54.46%	3.79%	1.81%	8/6/2025 (Estimated)
IOBT IO Biotech	-$86.08M	-$1.37	N/A	N/A	N/A	N/A	-86.56%	-75.24%	8/12/2025 (Estimated)
TXMD TherapeuticsMD	-$10.28M	N/A	0.00	∞	N/A	-207.77%	-14.08%	-9.61%	8/11/2025 (Estimated)
VTVT vTv Therapeutics	-$20.25M	-$3.01	N/A	∞	N/A	N/A	-184.64%	-47.29%	8/6/2025 (Estimated)

Latest TXMD, IOBT, ASRT, and VTVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	VTVT vTv Therapeutics	-$0.73	-$0.77	-$0.04	-$0.77	N/A	N/A
5/13/2025	Q1 2025	TXMD TherapeuticsMD	N/A	-$0.06	N/A	-$0.06	N/A	$0.39 million
5/12/2025	Q1 2025	ASRT Assertio	-$0.06	-$0.14	-$0.08	-$0.14	$27.52 million	$26.49 million
3/20/2025	Q4 2024	VTVT vTv Therapeutics	-$0.87	-$0.55	+$0.32	-$0.55	N/A	$0.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASRT Assertio	N/A	N/A	N/A	N/A	N/A
IOBT IO Biotech	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASRT Assertio	0.30	2.01	1.57
IOBT IO Biotech	N/A	5.37	5.37
TXMD TherapeuticsMD	N/A	2.03	2.03
VTVT vTv Therapeutics	N/A	6.69	6.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASRT Assertio	48.96%
IOBT IO Biotech	54.76%
TXMD TherapeuticsMD	30.74%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
ASRT Assertio	4.00%
IOBT IO Biotech	4.80%
TXMD TherapeuticsMD	2.30%
VTVT vTv Therapeutics	4.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASRT Assertio	20	95.78 million	92.42 million	Optionable
IOBT IO Biotech	30	65.88 million	64.37 million	Not Optionable
TXMD TherapeuticsMD	420	11.57 million	11.27 million	Optionable
VTVT vTv Therapeutics	9	3.20 million	3.15 million	Not Optionable

TXMD, IOBT, ASRT, and VTVT Headlines

Recent News About These Companies

Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Decreases By 24.1%

June 4 at 4:17 AM | americanbankingnews.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Down 24.1% in May

June 2, 2025 | marketbeat.com

vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Above Fifty Day Moving Average - Here's Why

May 26, 2025 | marketbeat.com

vTv resumes Phase III oral T1D drug study

May 21, 2025 | thepharmaletter.com

vTv Therapeutics Appoints Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer

May 19, 2025 | quiverquant.com

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 19, 2025 | globenewswire.com

vTv Therapeutics (NASDAQ:VTVT) Stock Passes Above 50-Day Moving Average - Here's Why

May 18, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT) and Precision BioSciences (DTIL)

May 17, 2025 | theglobeandmail.com

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025 | globenewswire.com

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

May 15, 2025 | globenewswire.com

vTv Therapeutics Appoints Barry Brown as Interim CFO

April 11, 2025 | tipranks.com

vTv Therapeutics initiated with a Buy at H.C. Wainwright

April 9, 2025 | markets.businessinsider.com

HC Wainwright & Co. Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation

April 9, 2025 | msn.com

vTv Therapeutics cleared to resume clinical trial of diabetes therapy

March 26, 2025 | ncbiotech.org

vTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last year

March 21, 2025 | markets.businessinsider.com

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

March 20, 2025 | globenewswire.com

vTv Therapeutics Inc.: vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

March 18, 2025 | finanznachrichten.de

Alliance Global says clinical hold lift ‘de-risking’ event for vTv Therapeutics

March 18, 2025 | markets.businessinsider.com

vTv Therapeutics says FDA has lifted clinical hold on cadisegliatin program

March 17, 2025 | markets.businessinsider.com

vTv Therapeutics stock surges on FDA update

March 17, 2025 | au.investing.com

Vtv Therapeutics Shares Halted as FDA Clinical Hold on Diabetes Treatment Lifted

March 17, 2025 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD, IOBT, ASRT, and VTVT Company Descriptions

Assertio NASDAQ:ASRT

$0.66 +0.01 (+1.50%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$0.67 +0.01 (+1.09%)

As of 06/6/2025 07:54 PM Eastern

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

IO Biotech NASDAQ:IOBT

$1.60 +0.10 (+6.67%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$1.60 0.00 (0.00%)

As of 06/6/2025 07:26 PM Eastern

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

TherapeuticsMD NASDAQ:TXMD

$1.25 +0.14 (+12.61%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$1.17 -0.08 (-6.40%)

As of 06/6/2025 07:19 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

vTv Therapeutics NASDAQ:VTVT

$16.67 0.00 (0.00%)

Closing price 06/6/2025 03:57 PM Eastern

Extended Trading

$16.80 +0.13 (+0.78%)

As of 06/6/2025 04:04 PM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time